Further study indicated the IRF1 seemed to play a key role in the transcriptional activation of interferon-inducible guanylate binding proteins (GBP1 and GBP2) [45], which subsequently induces T-lymphocyte immune response against the cancer cell spreading and proliferation [46]. This evidence concerns the gene GBP2 and cancer.